

SOMATIC MUTATION TESTING IN SOLID TUMOURS REQUEST FORM

INSTRUCTIONS FOR CLINICIANS:

- 1 Please complete this page in FULL
- 2 EMAIL this form and a copy of the original histopathology report to Mellab.Genetics@clinicallabs.com.au (alternatively FAX: 03 9594 8571)
- 3 For any enquiries, please phone: 03 9538 2259 or 1300 134 111

COMPLETE THE FOLLOWING DETAILS:

Patient Details		Clinical Information	
Name: Date of Birth: Gender: ☐ Male ☐ Female Mobile: Address: Medicare No: Health Fund: Fund No: Patient status at time sample was collected: ☐ Private patient in a private hospital, or approved day hospital facility ☐ Private patient in a recognised hospital ☐ Outpatient of a recognised hospital Hospital Name: Signature: Date:		Is this a new diagnosis? ☐ YES ☐ NO Has the patient been treated with systemic anti-tumour therapy? ☐ YES ☐ NO Patient Stage: Tumour Type: ☐ Colorectal carcinoma ☐ Non-small cell lung cancer ☐ Metastatic melanoma ☐ Cholangiocarcinoma ☐ Other	
Clinical stage and/or treatment status may determine eligibility for funding by Medicare or pharmaceutical access programs (see back of form). If this information is not indicated, the patient may be privately billed. Testing of samples that fall outside of the Medicare Eligibility Criteria will be billed privately to the patient.			
Test Required			
Gene Target	Tick if Required	Medicare Criteria Met?	
Cholangiocarcinoma Panels DNA Panel (<i>IDH1</i>) DNA & RNA Fusion Panel (<i>IDH1</i> & <i>FGFR2</i>)	☐ ☐	☐ YES ☐ YES	☐ NO ☐ NO
Colorectal Panel (<i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> , <i>PTEN</i> & <i>AKT1</i>)	☐	☐ YES	☐ NO
Lung Panels DNA Panel (<i>EGFR</i> , <i>KRAS</i> , <i>BRAF</i> , <i>ERBB2</i> , <i>NRAS</i> , <i>PIK3CA</i> , <i>AKT1</i> , <i>MAP2K1</i> , & <i>MET</i>) Comprehensive Lung Panel DNA & RNA (<i>EGFR</i> , <i>KRAS</i> , <i>BRAF</i> , <i>ERBB2</i> , <i>NRAS</i> , <i>PIK3CA</i> , <i>AKT1</i> , <i>MAP2K1</i> , <i>MET</i> , <i>ALK</i> , <i>ROS1</i> , <i>RET</i> , <i>NTRK1</i> , <i>NTRK2</i> , & <i>NTRK3</i>) RNA Fusion Panel (<i>MET</i> , <i>ALK</i> , <i>ROS1</i> , <i>RET</i> , <i>NTRK1</i> , <i>NTRK2</i> , & <i>NTRK3</i>) MET Exon 14 skipping (RNA testing) <i>Provided suitability of sample for testing.</i>	☐ ☐ ☐ ☐	☐ YES ☐ YES ☐ YES ☐ YES	☐ NO ☐ NO ☐ NO ☐ NO
Melanoma Panel (<i>BRAF</i> , <i>NRAS</i> , <i>CKIT</i>)	☐	☐ YES	☐ NO
Breast Panel (<i>PIK3CA</i> , <i>AKT1</i> , <i>ERBB2</i> , <i>TP53</i> & <i>PTEN</i>)	☐	Please see clinicallabs.com.au/cancer-services for current pricing.	
Comprehensive Somatic Gene Panel (see over page for pay by phone) (Visit clinicallabs.com.au/cancer-services for a current list of genes included.)	☐	Please see clinicallabs.com.au/cancer-services for current pricing.	
Referring Clinician Details		Specimen to be Tested ID	
Name: Address: Email: Phone: Fax: Mobile: Date Requested: Provider No: Referring Clinician Signature:		SPECIMEN LOCATION: LAB NO: BLOCK NO: Date of Collection:	
		Copy Doctor Details	
		Name: Address: Phone:	

IDH1 Mutation in Cholangiocarcinoma Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73319)	Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime.
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

IDH1 and FGFR2 Testing in Cholangiocarcinoma Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73329)	A nucleic acid-based multi-gene panel test of tumour tissue from a patient with cholangiocarcinoma requested by, or on behalf of, a specialist or consultant physician, if the test is to: (a) detect at least IDH1 variant status; and (b) detect the fusion or rearrangement status of at least FGFR2; and (c) determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme including a service described in item 73319. Applicable once per lifetime.
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

KRAS Mutation in Colorectal Cancer Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73338)	A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme (PBS) are fulfilled, if: (a) The test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3 and for; or (b) A RAS mutation is found
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

EGFR Mutation in Lung Cancer Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73337)	A test of tumour tissue from a patient diagnosed with non-small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to erlotinib or gefitinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

MET Exon 14 Skipping in Lung Cancer Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73436)	A test of tumour tissue from a patient diagnosed with locally advanced or metastatic non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician to determine if the requirements relating to MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk) status for access to tepotinib are fulfilled under the Pharmaceutical Benefits Scheme.
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

BRAF Mutation in Melanoma Test Funding Information		Criteria
1	Medicare Eligibility Criteria (Item 73336)	A test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib under Pharmaceutical Benefits Scheme (PBS) are fulfilled.
2	Private Payment	Where patients do not meet the eligibility criteria, a private fee will be charged. Please see clincallabs.com.au/cancer-services for current pricing.

Pay by phone for Somatic Mutation Tests:

Receipt # _____

Please call 1300 369 762 and select option 3 to make your payment over the phone. Lines are open Mon-Fri 9am-5pm (AEST).

For patients in WA, please call (08) 9442 7646. Lines are open Mon-Fri 8am-4pm (AWST).

Please note: For patient samples held by histopathology laboratories that are not part of the Clinical Labs network, a sample retrieval and processing fee may be applied and invoiced to the patient by the laboratory holding the sample stock. Patients who do not meet the Medicare eligibility criteria may be charged an out-of-pocket fee.

PRIVACY NOTE: This information provided will be used to assess any Medicare benefit payable for the services rendered and to facilitate the proper administration of Government health programs, and may be used to update enrolment records. Its collection is authorised by provisions of the Health Insurance Act 1973. The information may be disclosed to the Department of Health or to a person in the medical practice associated with this claim or as authorised/required by law.

Clinical Laboratories Pty Ltd A.B.N. 62 006 823 089